Research guide · Published July 23, 2026 · Sources checked July 23, 2026
FOXO4-DRI, p53, and cellular senescence: an evidence guide
FOXO4-DRI is a D-retro-inverso peptide designed to interfere with an interaction between the FOXO4 transcription factor and p53 in selected senescent-cell models. The name refers to FOXO4, or forkhead box O4—not a compound numbered ‘FOX-04.’
Short answer
The foundational hypothesis is that disrupting a FOXO4–p53 interaction can promote p53 redistribution and apoptosis in selected senescent cells. Later studies examined additional cell types and mouse models. This remains model-dependent preclinical research and does not establish a general anti-aging or longevity effect in humans.
Evidence boundary: The cited studies do not establish clinical safety, human longevity, broad rejuvenation, or effectiveness across all senescent-cell types. Catalog materials are supplied only for lawful nonclinical research and are not for human or animal use.
Comparison at a glance
| Evidence layer | Material and model | Key interpretation limit |
|---|---|---|
| Foundational study | FOXO4-DRI in senescent human fibroblast systems and aged or progeroid mice | One study does not establish universal senescent-cell selectivity |
| Keloid research | Senescence-associated keloid organ cultures and fibroblasts | A specialized scar model is not general aging evidence |
| Vascular-aging research | OGD-associated endothelial-cell models and naturally aged or progeroid mice | Cell and mouse vascular endpoints are not clinical outcomes |
| Molecular interpretation | FOXO4–p53 interaction, phosphorylated-p53 localization, and apoptosis-associated measurements | Pathway measurements do not verify a separately manufactured peptide batch |
| How was senescence identified? | Each study used its own model, induction context, and panel of senescence- or apoptosis-associated measurements | No single marker establishes a universal senescent-cell population |
| Why does peptide design matter? | The D-retro-inverso sequence and stereochemistry are part of the experimental material's identity | A name alone does not confirm sequence, stereochemistry, purity, or matched biological activity |
How to interpret the comparison
Cellular senescence is heterogeneous: triggers, tissues, markers, and survival pathways differ. A material that changes one senescent-cell model should not automatically be labeled a universal senolytic.
D-retro-inverso design changes residue chirality and sequence orientation to preserve selected side-chain topology while altering peptide properties. Exact sequence, stereochemistry, analytical identity, and the study material therefore matter when matching literature to a supplied batch.
The foundational fibroblast work, keloid experiments, and vascular-aging models use different biological contexts. Agreement around a proposed interaction can strengthen a hypothesis without proving equal selectivity or effect size across tissues.
When evaluating replication, compare how senescence was induced or identified, which controls were used, what apoptosis measurements were collected, and whether the tested material was analytically matched.
Primary sources
- Baar et al., Cell (2017) — Foundational cell and mouse study targeting the FOXO4–p53 interaction in selected senescence models. DOI: 10.1016/j.cell.2017.02.031
- Kong et al., Communications Biology (2025) — Keloid organ-culture and fibroblast research examining p53-serine-15 phosphorylation and FOXO4-DRI-associated apoptosis. DOI: 10.1038/s42003-025-07738-0
- Hu et al., Frontiers in Bioengineering and Biotechnology (2025) — Endothelial-cell and mouse vascular-aging models focused on FOXO4–p53 signaling and apoptosis-associated measurements. DOI: 10.3389/fbioe.2025.1729166
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.